Introduction
Syros (SYRS) is a biopharmaceutical company focused on developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases. Its leading drug is SY-1425, a selective retinoic acid receptor alpha agonist, or RAR? agonist, that is currently evaluated in a phase 2 trial in combination with azacitidine (Vidaza) on patients affected by acute myeloid leukemia (AML).
Syros is also developing SY-5609, an oral inhibitor of cyclin-dependent kinase 7 (CDK7), that is currently in the dose-escalation portion of a phase 1 study in patients with select